Reviews
IO-TKI vs Dual Checkpoint Inhibition for Bone Metastases in Metastatic ccRCC
Albuquerque et alJournal of bone oncology

Bone metastases affect approximately one-third of individuals with metastatic clear-cell renal cell carcinoma (ccRCC) and confer a poor prognosis. While immune-oncology (IO)-based regimens represent the standard first-line therapy, comparative efficacy between IO combined with a tyrosine kinase inhibitor (IO+TKI) versus dual immunotherapy (IO+IO) in this population has remained uncertain.
A systematic review and meta-analysis evaluated phase III randomized controlled trials assessing first-line IO combinations versus sunitinib in treatment-naïve metastatic ccRCC patients with baseline bone metastases and a median follow-up of at least 36 months. Three trials met the eligibility criteria: CLEAR (lenvatinib plus pembrolizumab), CheckMate 9ER (nivolumab plus cabozantinib), and CheckMate 214 (nivolumab plus ipilimumab). Fixed- and random-effects inverse-variance models were applied, pooling the IO+TKI studies and evaluating the single IO+IO trial separately.
Pooled analysis of the IO+TKI trials showed a significant improvement in progression-free survival (PFS) compared with sunitinib (HR 0.46, 95% CI 0.35–0.61; p < 0.0001; I² = 0%), whereas IO+IO showed no PFS benefit (HR 1.07, 95% CI 0.76–1.51). Pooling all three trials resulted in substantial heterogeneity (I² = 85.9%), and subgroup analysis confirmed a significant interaction between regimen class and PFS (p = 0.0002). For overall survival (OS), IO+TKI also improved OS over sunitinib (HR 0.66, 95% CI 0.50–0.88; p = 0.0041; I² = 0%), while IO+IO showed a non-significant trend toward improved OS (HR 0.82, 95% CI 0.61–1.11), without a significant difference between the two treatment classes for OS (p = 0.314). The authors concluded that treatment strategy may influence clinical outcomes in this high-risk patient subset.
Key Takeaways
- First-line IO plus TKI combinations significantly improved progression-free survival (HR 0.46, 95% CI 0.35–0.61; p < 0.0001) and overall survival (HR 0.66, 95% CI 0.50–0.88; p = 0.0041) compared with sunitinib in patients with metastatic clear-cell renal cell carcinoma and bone metastases, with no heterogeneity across trials (I² = 0%).
- Dual immunotherapy (IO+IO) showed no progression-free survival benefit over sunitinib (HR 1.07, 95% CI 0.76–1.51) and a non-significant trend toward improved overall survival (HR 0.82, 95% CI 0.61–1.11), with a significant interaction confirmed between treatment class and progression-free survival (p = 0.0002).
Read the original sourceJournal of bone oncology
